Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2023-04-27 Capital/Financing Update
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 95% confidence The document is a Prospectus Supplement filed pursuant to Rule 424(b)(3) related to a Registration Statement on Form S-1. It amends and supplements a previously filed Prospectus and includes information from an amended annual report on Form 10-K/A. The document primarily concerns the resale of common shares by selling shareholders and updates to the registration statement. It is a capital markets filing related to securities offering and shareholder resale, not a full annual report or financial statement. Therefore, it fits the Capital/Financing Update (CAP) category, which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 2723 characters, which is consistent with a supplement or update rather than a full report.
2023-04-27 English
FORM 10-K/A
Annual Report FY 2022
2023-04-27 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used to announce unscheduled material events or corporate changes. The content includes a prospectus supplement related to a securities offering and an announcement of the submission of an Investigational New Drug application to the FDA. It also includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document primarily serves as a regulatory filing to disclose material events and updates to investors and the SEC. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other specific categories.
2023-04-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text specifically mentions the announcement of a press release regarding the submission of an Investigational New Drug application. The document is short (3654 characters) and primarily serves as an announcement of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-04-10 English
424B3
Board/Management Information Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 3, 2023, reporting the departure of a director who will not stand for re-election at the upcoming Annual Meeting. The key content is the announcement of a change in the company's board of directors. There are no financial statements or detailed financial data present, and the document is not a full annual or quarterly report. It specifically falls under announcements related to board or management changes. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length (6180 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2023-04-03 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 29, 2023, by ProMIS Neurosciences Inc. The key content is under Item 5.02, which reports the departure of a director, Richard Gregory, who will not stand for re-election and will end his term at the upcoming Annual Meeting. This is a clear announcement of a change in the company's board of directors. There is no financial data or report attached, and the document is relatively short (3585 characters). Therefore, it fits the category of Board/Management Information (MANG).
2023-04-03 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.